Former Eli Lilly executive, David E. Thompson, joins Bayhill Therapeutics board of directors
Palo Alto, CA, April 6, 2006 – Bayhill Therapeutics Inc., a privately held biopharmaceutical company, today announced the appointment of David E. Thompson to the Bayhill Board as an independent director.
“David’s broad background in product strategy, business development and corporate finance complements the skills of our Board and management team,” said Mark W. Schwartz, Ph.D., President and CEO of Bayhill. “David’s demonstrated business development expertise is central to Bayhill as we develop our antigen-specific technology pipeline and form strategic partnerships with pharmaceutical companies,” he said.
Mr. Thompson joins the Board following his retirement from Eli Lilly & Company where he was Vice President of Corporate Strategy & Business Development. In this role, Mr. Thompson’s primary responsibilities were to direct the company’s activities related to corporate strategy, product licensing, R&D alliances, M&A, Lilly’s venture group and the alliance management team.
Under his leadership, Lilly established over 250 partnerships significantly strengthening the company’s product and technology portfolio while establishing an industry leading position in partnering and alliance capabilities.
“Bayhill has a variety of clinically relevant programs that we believe begin to address the unmet needs facing patients with multiple sclerosis and physicians who treat them,” said Mr. Thompson. “I am working with the management team and the Board as Bayhill plans and executes its partnering programs.”
About Bayhill Therapeutics
Bayhill Therapeutics Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapeutics that fundamentally alter the way autoimmune diseases are treated. The company has developed two therapeutic platforms with broad applicability to a range of autoimmune diseases. Bayhill’s BHT-DNA autoimmune vaccine is designed to eliminate disease-causing cells without affecting normal protective immune system cells. BHT-DNA is being studied in a recently completed Phase II trial for multiple sclerosis and a Phase I/II trial for autoimmune diabetes. Bayhill’s second therapeutic platform is an oligonucleotide; the first product candidate is in preclinical development for systemic lupus erythematosus.
More information about Bayhill Therapeutics is available at www.bayhilltx.com.
CONTACTS
Mark W. Schwartz, Ph.D.
President, CEO, Director
Bayhill Therapeutics Inc.
650-320-2800
mschwartz@bayhilltx.com
or
Fred Kurland
Chief Financial Officer
Bayhill Therapeutics Inc.
650-320-2800
fkurland@bayhilltx.com
CORPORATE COMMUNICATIONS CONTACT:
Lorraine Ruff
206-444-0022 office
lorraine@thinkmilestones.com
